Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low-grade lymphoma.

Jane N Winter1, Randy D Gascoyne, Koen Van Besien

  • 1Feinberg School of Medicine, Northwestern University, Div. of Hematology/Oncology, Chicago, IL 6061-4538, USA.

Hematology. American Society of Hematology. Education Program
|November 25, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of skin microvasculature C5b-9 and MASP2 deposition in transplant-associated thrombotic microangiopathy.

Leukemia & lymphoma·2026
Same author

Validation and Clinical Meaningfulness of the 18-item National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index in Patients With Lymphoma.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

ATRA treatment in the emergency department is associated with reduced early mortality in acute promyelocytic leukemia-a real-world multicenter retrospective cohort analysis.

Leukemia & lymphoma·2026
Same author

Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records.

EClinicalMedicine·2026
Same author

Serological pseudoprogression of multiple myeloma after treatment with teclistamab.

Leukemia & lymphoma·2025
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Folicular lymphoma (FL) exhibits diverse clinical behaviors due to complex biology. Research integrates molecular insights with clinical practice for targeted treatments and rational biomarker-based therapy selection.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Folicular lymphoma (FL) is the second most common non-Hodgkin lymphoma.
  • FL displays significant heterogeneity in clinical behavior and underlying biology.
  • Advancing molecular understanding of FL aims to bridge research and clinical practice.

Purpose of the Study:

  • To review the histologic, cytogenetic, and biologic features of FL contributing to clinical variability.
  • To discuss the evolving landscape of FL treatment options and the role of clinical trials.
  • To update on outcomes of autologous and allogeneic stem cell transplantation for FL.

Main Methods:

  • Review of FL pathology, including diagnostic aspects relevant to clinicians.
  • Analysis of current and emerging treatment strategies for FL.

Related Experiment Videos

  • Summary of stem cell transplantation outcomes and patient selection criteria.

    • Main Results:

    • Understanding FL biology is key to explaining clinical variability and predicting outcomes.
    • Treatment selection for FL is complex, involving diverse approaches from observation to transplantation.
    • Stem cell transplantation, particularly reduced-intensity allogeneic transplantation, shows promise for FL.

    Conclusions:

    • Integrating molecular insights with clinical data is crucial for personalized FL treatment.
    • Clinical trials remain essential for determining optimal FL management strategies.
    • Further research into lymphomagenesis and therapeutic interventions is ongoing.